The biotechnology sector needs to share its health care accomplishments with consumers and lawmakers, highlighting the contributions it makes through drug development, newly elected BIO chairwoman Rachel King said. "Most people have probably benefited or know someone who has benefited. We need to communicate, as part of that, that to get to those new medicines takes a long time and a lot of investment," she said. King, the president and CEO of GlycoMimetics, said the FDA's efforts to hasten the approval process are crucial for limiting investor uncertainty and bringing new drugs to patients.
Published in Brief: